170863 ⎘
Detection or diagnosis of diseases; Cardiovascular disorders Arterial hypertension
METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC
#2SHBG AND IBP4 ANTIBODIES AND METHODS USING SAME
#3Cilia Protein as Biomarkers and Methods of Use
#4Aptamer for specifically recognizing soluble ST2 protein and application of the same
#5NANOPARTICLE PROBES AND METHODS OF MAKING AND USE THEREOF
#6THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION
#7METHOD FOR THE DIAGNOSIS AND TREATMENT OF ESSENTIAL PRIMARY HYPERTENSION
#8CIRCULATING NEDD9 IS INCREASED IN PULMONARY ARTERIAL HYPERTENSION
#9Synchronous Detection Method of Medicaments Influencing ARR in the Detection Process of Renin Activity by Liquid Chromatography-Tandem Mass Spectrometry
#10Pulmonary hypertension biomarker
#11INSULIN-LIKE GROWTH FACTOR AXIS PROTEINS AS CIRCULATING PULMONARY ARTERIAL HYPERTENSION BIOMARKERS
#12Method for the diagnosis and treatment of essential primary hypertension
#13NANOPARTICLE PROBES AND METHODS OF MAKING AND USE THEREOF
#14Methods for Increasing the Selective Efficacy of Gene Therapy Using CAR Peptide and Heparan-Sulfate Mediated Macropinocytosis
#15Methods of detecting and treating pulmonary hypertension
#16Machine assay and analysis for selecting antihypertensive drugs
#17Therapeutic regimen for hypertension
#18Nanoparticle probes and methods of making and use thereof
#19PULMONARY HYPERTENSION BIOMARKER
#20BIOMARKERS FOR THE DIAGNOSIS OF INFLAMMATION-RELATED DISEASES
#21Compositions and methods for detecting, treating and preventing diseases and disorders
#22METHODS FOR PREDICTING RISK OF DEVELOPING HYPERTENSION
#23USE OF CD146 AS A MARKER OF THE VASCULAR WALL TENSION
#24Composition for diagnosing, preventing, or treating vascular smooth muscle cell proliferative diseases using FGF12
#25Therapeutic regimen for hypertension
#26METHOD OF DIGITIZING NUTRITIONAL STATUS, MUSCLE TURNOVER, AND RISK ASSESSMENT
#27Diagnostics for pulmonary arterial hypertension and sudden cardiac death
#28Isolation of pulmonary arterial endothelial cells from patients with pulmonary vascular disease and uses thereof
#29Nanoparticle probes and methods of making and use thereof
#30Methods for Increasing the Selective Efficacy of Gene Therapy Using CAR Peptide and Heparan Sulfate Mediated Macropinocytosis
#31Nanoparticle probes and methods of making and use thereof
#32Methods for predicting risk of developing hypertension
#33Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
#34Therapeutic regimen for hypertension
#35PULMONARY HYPERTENSION BIOMARKER
#36Compositions and methods of inhibiting histone deacetylases
#37Biomarkers of mineralocorticoid receptor activation
#38Methods of Diagnosis and Treatment for Pulmonary Arterial Hypertension
#39Methods for increasing the selective efficacy of gene therapy using CAR peptide and heparan-sulfate mediated macropinocytosis
#40Use of Bufodienolides in Diagnosing and Treating Essential Hypertension
#41METHOD FOR THE DIAGNOSIS OF SYSTEMIC SCLERODERMA OR OF PULMONARY ARTERIAL HYPERTENSION
#42Isolation of pulmonary arterial endothelial cells from patients with pulmonary vascular disease and uses thereof
#43Compositions and methods for detecting, treating and preventing diseases and disorders
#44Compositions and methods for identifying and diagnosing salt sensitivity of blood pressure
#45Method for diagnosis of pulmonary involvement in systemic sclerosis
#46Compositions and methods of using micro RNAs
#47Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
#48Methods for predicting risk of developing hypertension
#49Detection method
#50Method of identifying therapies for pulmonary hypertension
#51Antibody that specifically binds to an epitope in the tureet region of a human Kir channel
#52METHODS FOR DIAGNOSIS AND PROGNOSIS OF PULMONARY HYPERTENSION
#53NEUROTROPHINS AND USES THEREOF
#54METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2
#55PHENOXYBENZAMINE ASSAY
#56Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States
#57Diagnosis of preeclampsia
#58BIOMARKERS FOR THE DIAGNOSIS OF PROSTATE CANCER IN A NON-HYPERTENSIVE POPULATION
#59METHODS FOR DIAGNOSIS AND PROGNOSIS OF PULMONARY HYPERTENSION
#60METHOD FOR THE DIAGNOSIS OF SYSTEMIC SCLERODERMA OR OF PULMONARY ARTERIAL HYPERTENSION
#61Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
#62Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
#63Biomarkers of Mineralocorticoid Receptor Activation
#64Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands
#65VEGF polymorphisms and anti-angiogenesis therapy
#66CATESTATIN (CST) AND ITS VARIANTS FOR TREATMENT OF CARDIOVASCULAR AND METABOLIC DISORDERS
#67TETRAHYDRO-ISOALPHA ACID COMPOSITIONS AND METHODS FOR WEIGHT MANAGEMENT
#68Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
#69Prophylactic/therapeutic agents for lifestyle-related diseases
#70Biomarkers for diabetes, obesity, and/or hypertension
#71REAL-TIME ASSAYS OF NEURO-HUMORAL FACTORS TO ASSESS CARDIOVASCULAR STRESS
#72Method for diagnosing pulmonary artery hypertension
#73Genetic variants in a hypertension susceptibility gene Stk39 and uses thereof
#74Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
#75Diagnosis of preeclampsia
#76Detection of hypertension using glucuronidated metabolic products
#77Method for diagnosis of a disease involving an anti-endothelin-receptor antibody
#78Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
#79METHOD FOR THE DIAGNOSIS AND TREATMENT OF SALT SENSITIVITY AND RELATED CONDITIONS
#80Method for the Diagnosis and Treatment of Conditions Involving Aberrant Erythrocyte Potassium Levels
#81Adiponectin for treatment of various disorders
#82Prostasin partial peptide and anti-prostasin antibody
#83Biological markers for longevity and diseases and uses thereof
#84Assays for erectile and bladder dysfunction and vascular health
#85Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
#86Real-Time Assays Of Neuro-Humoral Factors To Assess Cardiovascular Stress
#87SCREENING FOR GESTATIONAL DISORDERS
#88Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
#89NATRIURETIC PEPTIDE RATIO FOR DIAGNOSING CARDIAC DYSFUNCTIONS
#90Method and Apparatus for Diagnosing Pre-eclampsia
#91SALT-SENSITIVE HYPERTENSION
#92Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
#93Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
#94Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
#95Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
#96Detection of hypertension using glucuronidated metabolic products
#97Hypoxia inducible factor 2α for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
#98Methods and agents for regulating angiotensin activity
#99Diagnosis of preeclampsia
#100Nucleic acids and polypeptides useful for diagnosing complications of pregnancy
#101Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
#102Biological markers for longevity and diseases and uses thereof
#103Diagnosis of disease and monitoring of therapy using gene expression analysis of peripheral blood cells
#104Brain natriuretic peptide spliced variant
#105Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases
#106Screening for gestational disorders
#107Methods and agents for regulating angiotensin activity
#108Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
#109Method for evaluating and treating hypertension
#110Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension